{"count": 7, "results": [{"_id": "32968437", "pmid": 32968437, "pmcid": "PMC7500004", "title": "Caduet enhances connexin 43 phosphorylation in left ventricular and thoracic aorta of SH model rats", "journal": "Exp Ther Med", "authors": ["Huang X", "Yang J", "Song B", "Wang N", "Ma M", "Wang H", "Wang S", "Hao S", "Cheng G"], "date": "2020-11-01T00:00:00Z", "doi": "10.3892/etm.2020.9207", "meta_date_publication": "2020 Nov", "meta_volume": "20", "meta_issue": "5", "meta_pages": "80", "score": 50276.68, "text_hl": "...@<m>CHEMICAL_amlodipine_atorvastatin_drug_combination</m> @CHEMICAL_MESH:C487936 @@@Caduet@@@, also known as @CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@amlodipine besylate@@@ and @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin calcium@@@ (@CHEMICAL_Americium @CHEMICAL_MESH:D000576 @@@AM@@@ + @CHEMICAL_Astatine @CHEMICAL_MESH:D001246 @@@AT@@@) tablet, can improve @DISEASE_Vascular_Remodeling @DISEASE_MESH:D066253 @@@cardiac and vascular remodeling@@@ in @SPECIES_9606 @@@patients@@@ with spontaneous @<m>DISEASE_Hypertension</m> @DISEASE_MESH:D006973 @@@hypertension@@@ (@<m>DISEASE_Hypertension</m> @DISEASE_MESH:D006973 @@@SH@@@), but the underlying mechanism remains unknown. ", "citations": {"NLM": "Huang X, Yang J, Song B, Wang N, Ma M, Wang H, Wang S, Hao S, Cheng G. Caduet enhances connexin 43 phosphorylation in left ventricular and thoracic aorta of SH model rats Exp Ther Med. 2020 Nov;20(5):80. PMID: 32968437", "BibTeX": "@article{32968437, title={Caduet enhances connexin 43 phosphorylation in left ventricular and thoracic aorta of SH model rats}, author={Huang X and Yang J and Song B and Wang N and Ma M and Wang H and Wang S and Hao S and Cheng G}, journal={Exp Ther Med}, volume={20}, number={5}, pages={80}}"}}, {"_id": "15963213", "pmid": 15963213, "title": "Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.", "journal": "Int J Clin Pract", "authors": ["Cowie MR"], "date": "2005-07-01T00:00:00Z", "doi": "10.1111/j.1368-5031.2005.00601.x", "meta_date_publication": "2005 Jul", "meta_volume": "59", "meta_issue": "7", "meta_pages": "839-46", "score": 50057.17, "text_hl": "Single-pill @CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@amlodipine besylate@@@/@CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin calcium@@@ (@<m>CHEMICAL_amlodipine_atorvastatin_drug_combination</m> @CHEMICAL_MESH:C487936 @@@Caduet@@@), Pfizer Inc, NY, USA) is the first therapy aimed at the simultaneous treatment of @<m>DISEASE_Hypertension</m> @DISEASE_MESH:D006973 @@@hypertension@@@ (@<m>DISEASE_Hypertension</m> @DISEASE_MESH:D006973 @@@HTN@@@) and dyslipidaemia (DYS). ", "citations": {"NLM": "Cowie MR. Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. Int J Clin Pract. 2005 Jul;59(7):839-46. PMID: 15963213", "BibTeX": "@article{15963213, title={Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.}, author={Cowie MR}, journal={Int J Clin Pract}, volume={59}, number={7}, pages={839-46}}"}}, {"_id": "15350169", "pmid": 15350169, "title": "Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease.", "journal": "Expert Rev Cardiovasc Ther", "authors": ["Frishman WH", "Zuckerman AL"], "date": "2004-09-01T00:00:00Z", "doi": "10.1586/14779072.2.5.675", "meta_date_publication": "2004 Sep", "meta_volume": "2", "meta_issue": "5", "meta_pages": "675-81", "score": 50053.016, "text_hl": "Combination therapy of @CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@amlodipine besylate@@@ (Norvasc, Pfizer Ltd) with @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin calcium@@@ (Lipitor, Pfizer Ltd), marketed as @<m>CHEMICAL_amlodipine_atorvastatin_drug_combination</m> @CHEMICAL_MESH:C487936 @@@Caduet@@@ (Pfizer Ltd) is the first dual-therapy compound designed to treat @<m>DISEASE_Hypertension</m> @DISEASE_MESH:D006973 @@@hypertension@@@ and/or @DISEASE_Angina_Pectoris @DISEASE_MESH:D000787 @@@angina@@@ and @DISEASE_Dyslipidemias @DISEASE_MESH:D050171 @@@dyslipidemia@@@ concurrently with a single daily pill in the full range of dosing combinations. ", "citations": {"NLM": "Frishman WH, Zuckerman AL. Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Expert Rev Cardiovasc Ther. 2004 Sep;2(5):675-81. PMID: 15350169", "BibTeX": "@article{15350169, title={Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease.}, author={Frishman WH and Zuckerman AL}, journal={Expert Rev Cardiovasc Ther}, volume={2}, number={5}, pages={675-81}}"}}, {"_id": "22809114", "pmid": 22809114, "title": "Impact of age and gender on blood pressure and low-density lipoprotein cholesterol reduction: results of a pooled analysis.", "journal": "Curr Med Res Opin", "authors": ["Feldman RD", "Flack J", "Howes L", "Jenssen T", "Reeves R", "Shi H", "Westergaard M", "Hobbs FD", "GEMINI US, GEMINI AALA, JEWEL 1 and 2 and CAPABLE investigators"], "date": "2012-09-01T00:00:00Z", "doi": "10.1185/03007995.2012.713339", "meta_date_publication": "2012 Sep", "meta_volume": "28", "meta_issue": "9", "meta_pages": "1421-33", "score": 50050.324, "text_hl": "METHODS: Data from five, 14-20-week, open-label, multi-national studies (GEMINI US, GEMINI-Australia, Asia, Latin-America, Africa/Middle-East [AALA], JEWEL 1, JEWEL 2, and the Clinical Utility of @<m>CHEMICAL_amlodipine_atorvastatin_drug_combination</m> @CHEMICAL_MESH:C487936 @@@Caduet@@@ in Simultaneously Achieving @<m>DISEASE_Hypertension</m> @DISEASE_MESH:D006973 @@@Blood Pressure@@@ and @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@Lipid@@@ End Points [CAPABLE]) were pooled. ", "citations": {"NLM": "Feldman RD, Flack J, Howes L, Jenssen T, Reeves R, Shi H, Westergaard M, Hobbs FD, GEMINI US, GEMINI AALA, JEWEL 1 and 2 and CAPABLE investigators. Impact of age and gender on blood pressure and low-density lipoprotein cholesterol reduction: results of a pooled analysis. Curr Med Res Opin. 2012 Sep;28(9):1421-33. PMID: 22809114", "BibTeX": "@article{22809114, title={Impact of age and gender on blood pressure and low-density lipoprotein cholesterol reduction: results of a pooled analysis.}, author={Feldman RD and Flack J and Howes L and Jenssen T and Reeves R and Shi H and Westergaard M and Hobbs FD and GEMINI US, GEMINI AALA, JEWEL 1 and 2 and CAPABLE investigators}, journal={Curr Med Res Opin}, volume={28}, number={9}, pages={1421-33}}"}}, {"_id": "25335530", "pmid": 25335530, "pmcid": "PMC4216336", "title": "Chronic unilateral chemosis following the use of amlodipine besylate", "journal": "BMC Ophthalmol", "authors": ["Kim KH", "Kim WS"], "date": "2014-10-21T00:00:00Z", "doi": "10.1186/1471-2415-14-124", "meta_date_publication": "2014 Oct 21", "meta_volume": "14", "meta_issue": "", "meta_pages": "124", "score": 50047.094, "text_hl": "He had been treated for @<m>DISEASE_Hypertension</m> @DISEASE_MESH:D006973 @@@hypertension@@@ and @DISEASE_Hyperlipidemias @DISEASE_MESH:D006949 @@@hyperlipidemia@@@ for the previous 5 months with once daily @CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@amlodipine besylate@@@/@CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@ (@<m>CHEMICAL_amlodipine_atorvastatin_drug_combination</m> @CHEMICAL_MESH:C487936 @@@Caduet@@@) and @CHEMICAL_candesartan_cilexetil @CHEMICAL_MESH:C077793 @@@candesartan cilexetil@@@ (Atacand). ", "citations": {"NLM": "Kim KH, Kim WS. Chronic unilateral chemosis following the use of amlodipine besylate BMC Ophthalmol. 2014 Oct 21;14():124. PMID: 25335530", "BibTeX": "@article{25335530, title={Chronic unilateral chemosis following the use of amlodipine besylate}, author={Kim KH and Kim WS}, journal={BMC Ophthalmol}, volume={14}, pages={124}}"}}, {"_id": "18800143", "pmid": 18800143, "title": "Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).", "journal": "J Hum Hypertens", "authors": ["Erdine S", "Ro YM", "Tse HF", "Howes LG", "Aguilar-Salinas CA", "Chaves H", "Guindy R", "Chopra P", "Moller RA", "Schou IM", "Gemini-AALA Investigators"], "date": "2009-03-01T00:00:00Z", "doi": "10.1038/jhh.2008.114", "meta_date_publication": "2009 Mar", "meta_volume": "23", "meta_issue": "3", "meta_pages": "196-210", "score": 50046.508, "text_hl": "The Gemini-AALA (Australia, Asia, Latin America, Africa/Middle East) study evaluated the efficacy and safety of single-pill @CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@amlodipine@@@/@CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@ (@<m>CHEMICAL_amlodipine_atorvastatin_drug_combination</m> @CHEMICAL_MESH:C487936 @@@Caduet@@@) for the treatment of @SPECIES_9606 @@@patients@@@ of diverse ethnicity with concomitant @<m>DISEASE_Hypertension</m> @DISEASE_MESH:D006973 @@@hypertension@@@ and dyslipidaemia. ", "citations": {"NLM": "Erdine S, Ro YM, Tse HF, Howes LG, Aguilar-Salinas CA, Chaves H, Guindy R, Chopra P, Moller RA, Schou IM, Gemini-AALA Investigators. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Hum Hypertens. 2009 Mar;23(3):196-210. PMID: 18800143", "BibTeX": "@article{18800143, title={Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).}, author={Erdine S and Ro YM and Tse HF and Howes LG and Aguilar-Salinas CA and Chaves H and Guindy R and Chopra P and Moller RA and Schou IM and Gemini-AALA Investigators}, journal={J Hum Hypertens}, volume={23}, number={3}, pages={196-210}}"}}, {"_id": "22991979", "pmid": 22991979, "title": "Changes in calculated coronary heart disease risk using proactive multifactorial intervention versus continued usual care in Latin-American and non-Latin-American patients enrolled in the CRUCIAL trial.", "journal": "Curr Med Res Opin", "authors": ["Pavia A", "Zamorano J", "Sutradhar S", "Yunis C", "CRUCIAL Investigators"], "date": "2012-10-01T00:00:00Z", "doi": "10.1185/03007995.2012.725391", "meta_date_publication": "2012 Oct", "meta_volume": "28", "meta_issue": "10", "meta_pages": "1667-76", "score": 50041.527, "text_hl": "The PMI strategy was implemented by the inclusion of single-pill @<m>CHEMICAL_amlodipine_atorvastatin_drug_combination</m> @CHEMICAL_MESH:C487936 @@@amlodipine/atorvastatin@@@ (SPAA) in the @SPECIES_9606 @@@patients@@@' treatment regimen. ", "citations": {"NLM": "Pavia A, Zamorano J, Sutradhar S, Yunis C, CRUCIAL Investigators. Changes in calculated coronary heart disease risk using proactive multifactorial intervention versus continued usual care in Latin-American and non-Latin-American patients enrolled in the CRUCIAL trial. Curr Med Res Opin. 2012 Oct;28(10):1667-76. PMID: 22991979", "BibTeX": "@article{22991979, title={Changes in calculated coronary heart disease risk using proactive multifactorial intervention versus continued usual care in Latin-American and non-Latin-American patients enrolled in the CRUCIAL trial.}, author={Pavia A and Zamorano J and Sutradhar S and Yunis C and CRUCIAL Investigators}, journal={Curr Med Res Opin}, volume={28}, number={10}, pages={1667-76}}"}}]}